Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.45 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.45 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL25238080 | 1.00 | BACE1 (0.86) | BACE1TSHRBCHETRPC3TRPC4 | |
| Succinic Acid SCHEMBL29012266 | 1.00 | BACE1 (0.86) | BACE1TSHRBCHETRPC3TRPC4 | |
| Succinic Acid SCHEMBL29489143 | 1.00 | BACE1 (0.86) | BACE1TSHRBCHETRPC3TRPC4 | |
| Succinic Acid SCHEMBL29489144 | 1.00 | BACE1 (0.86) | BACE1TSHRBCHETRPC3TRPC4 | |
| Succinic Acid SCHEMBL29012249 | 1.00 | BACE1 (0.86) | BACE1TSHRBCHETRPC3TRPC4 | |
| SCHEMBL2444189 | 0.93 | BACE1 (1.00) | BACE1TSHRBCHETRPC3TRPC4 | |
| SCHEMBL29489139 | 0.93 | BACE1 (1.00) | BACE1TSHRBCHETRPC3TRPC4 | |
| SCHEMBL29489140 | 0.93 | BACE1 (1.00) | BACE1TSHRBCHETRPC3TRPC4 | |
| Sulfuric Acid SCHEMBL25282862 | 0.91 | BACE1 (0.89) | BACE1TSHRBCHETRPC3TRPC4 | |
| Sulfuric Acid SCHEMBL29012236 | 0.91 | BACE1 (0.89) | BACE1TSHRBCHETRPC3TRPC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4222144-B1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2026-05-20 | — | — | EP | claimed |
| US-20250205226-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF SENSORY NEURON DISEASES | ALZPROTECT (FR) | 2025-06-26 | — | — | US | claimed |
| US-20250041290-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | ALZPROTECT (FR) | 2025-02-06 | — | — | US | claimed |
| EP-4452262-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H- BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | Alzprotect (FR) | 2024-10-30 | — | — | EP | claimed |
| US-20230391729-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2023-12-07 | — | — | US | claimed |
| EP-4222144-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | Alzprotect (FR) | 2023-08-09 | — | — | EP | claimed |
| WO-2023117990-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | ALZPROTECT (FR) | 2023-06-29 | — | — | WO | claimed |
| WO-2022069654-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2022-04-07 | — | — | WO | claimed |
| EP-4222144-B1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-20250205226-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF SENSORY NEURON DISEASES | ALZPROTECT (FR) | 2025-06-26 | — | — | US | disclosed |
| US-20250041290-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | ALZPROTECT (FR) | 2025-02-06 | — | — | US | disclosed |
| EP-4452262-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H- BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | Alzprotect (FR) | 2024-10-30 | — | — | EP | disclosed |
| US-20230391729-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2023-12-07 | — | — | US | disclosed |
| EP-4222144-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | Alzprotect (FR) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023117990-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | ALZPROTECT (FR) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022069654-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391729-A1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | SDHA, SDHB, SUCNR1 | DRD2 1608/4885DRD4 2120/4885DRD3 1213/4885 |
| US-20250041290-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | SMN1; SMN2, NLN, SDHA | DRD2 2826/4885DRD4 3502/4885DRD3 2063/4885 |
| US-20250205226-A1 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF SENSORY NEURON DISEASES | NLN, SCN3A, INA | DRD2 1428/4885DRD4 1642/4885DRD3 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.